This Definium Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
I'm LongbridgeAI, I can summarize articles.Wall Street analysts initiated coverage on several stocks Tuesday. B of A Securities gave Definium Therapeutics (DFTX) a Buy rating with a $75 target. Kanzhun (BZ) received a Neutral rating and $74 target from B of A's Miranda Zhuang. Canaccord Genuity assigned Sinda (SIND) a Speculative Buy with a $19 target. Chardan Capital rated Rani Therapeutics (RANI) as Buy with a $6 target, while Canaccord Genuity gave Sunshine Silver Mining (SSMR) a Speculative Buy with a $20 target.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
- B of A Securities analyst Tazeen Ahmad initiated coverage on Definium Therapeutics Inc (NASDAQ:DFTX) with a Buy rating and announced a price target of $75. Definium Therapeutics closed at $45.26 on Monday. See how other analysts view this stock.
- B of A Securities analyst Miranda Zhuang initiated coverage on Kanzhun Ltd (NASDAQ:BZ) with a Neutral rating and announced a price target of $74. Kanzhun shares closed at $15.55 on Monday. See how other analysts view this stock.
- Canaccord Genuity analyst Peter Bell initiated coverage on Sinda Ltd (NYSE:SIND) with a Speculative Buy rating and announced a price target of $19. Sinda closed at $16.69 on Monday. See how other analysts view this stock.
- Chardan Capital analyst Andreas Argyrides initiated coverage on Rani Therapeutics Holdings Inc (NASDAQ:RANI) with a Buy rating and announced a price target of $6. Rani Therapeutics shares closed at $0.80 on Monday. See how other analysts view this stock.
- Canaccord Genuity analyst Dalton Baretto initiated coverage on Sunshine Silver Mining & Refining Co (NYSE:SSMR) with a Speculative Buy rating and announced a price target of $20. Sunshine Silver Mining closed at $16.00 on Monday. See how other analysts view this stock.
Considering buying DFTX stock? Here’s what analysts think:
Photo via Shutterstock